243 related articles for article (PubMed ID: 36293054)
1. The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms.
Butnariu LI; Gorduza EV; Florea L; Țarcă E; Moisă ȘM; Trandafir LM; Stoleriu S; Bădescu MC; Luca AC; Popa S; Radu I; Cojocaru E
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293054
[TBL] [Abstract][Full Text] [Related]
2. Genetic Causes of Vascular Malformations and Common Signaling Pathways Involved in Their Formation.
Rose AL; Cathey SS
Dermatol Clin; 2022 Oct; 40(4):449-459. PubMed ID: 36243432
[TBL] [Abstract][Full Text] [Related]
3. Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
Tsujioka Y; Nozaki T; Niimi Y; Starkey J; Hasegawa D; Kondo M; Enokizono M; Makidono A; Kono T; Jinzaki M
Clin Imaging; 2022 Sep; 89():162-173. PubMed ID: 35849880
[TBL] [Abstract][Full Text] [Related]
4. The genetics of vascular birthmarks.
Mahajan P; Bergstrom KL; Phung TL; Metry DW
Clin Dermatol; 2022; 40(4):313-321. PubMed ID: 35181412
[TBL] [Abstract][Full Text] [Related]
5. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
6. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Shimano KA; Eng W; Adams DM
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29603. PubMed ID: 35253343
[TBL] [Abstract][Full Text] [Related]
7. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
8. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
9. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Franklin RA; Montalto G; Cervello M; Libra M; Candido S; Malaponte G; Mazzarino MC; Fagone P; Nicoletti F; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Chiarini F; Evangelisti C; Cocco L; Martelli AM
Oncotarget; 2012 Oct; 3(10):1068-111. PubMed ID: 23085539
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
12. Vascular anomalies: molecular bases, genetic testing and therapeutic approaches.
Paolacci S; Zulian A; Bruson A; Manara E; Michelini S; Mattassi RE; Lee BB; Amato B; Bertelli M
Int Angiol; 2019 Apr; 38(2):157-170. PubMed ID: 30938497
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways and possible therapies for head and neck vascular anomalies.
Coulie J; Boon L; Vikkula M
J Oral Pathol Med; 2022 Nov; 51(10):878-887. PubMed ID: 35610188
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
15. Molecular changes associated with vascular malformations.
Fereydooni A; Dardik A; Nassiri N
J Vasc Surg; 2019 Jul; 70(1):314-326.e1. PubMed ID: 30922748
[TBL] [Abstract][Full Text] [Related]
16. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
18. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
20. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
